New brain cancer combo shows early safety signal
NCT ID NCT03535350
Summary
This early-stage study is testing whether adding the drug ibrutinib to standard radiation and chemotherapy (temozolomide) is safe for people newly diagnosed with glioblastoma, an aggressive brain cancer. Researchers want to find the highest safe dose of ibrutinib and see if radiation helps deliver more of the drug to the brain tumor. The study enrolled 36 participants with two different genetic types of glioblastoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.